04 Aug 2013

Ganfort (Bimatoprost / Timolol) - Italia

ATC: S01ED
SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
BETA BLOCKING AGENTS
Ganfort

Last Updated on 04 Aug 2013 by EPG Health Media Staff.
Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page.

Ganfort Indication

Riduzione della pressione intraoculare (PIO) in pazienti adulti con glaucoma ad angolo aperto o con ipertensione oculare, che non rispondono adeguatamente ai beta-bloccanti o agli analoghi delle prostaglandine per uso topico.

Ganfort Generic Name

Bimatoprost / Timolol

Type

POM

Summary Product Characteristics (SPCs) Links
Riassunto delle Caratteristiche del Prodotto - Ganfort (external site)

Free Medical Education Resources

Selected content related to Ganfort (Bimatoprost / Timolol)

Clinical Trials

Journals

  • A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension.1
    Pfennigsdorf S, de Jong L, Makk S, Fournichot Y, Bron A, Morgan-Warren RJ, Maltman J.
    Clin Ophthalmol. 2013;7:1219-25. doi: 10.2147/OPTH.S41885. Epub 2013 Jun 21.

    Objective: The aim of this study was to evaluate the safety and efficacy of a fixed combination of bimatoprost 0.03% and timolol (BTFC) in a clinical setting, in a large sample of patients with primary open-angle glaucoma or ocular hypertension and insufficient intraocular pressure (IOP) lowering on prior therapy.
    Conclusion: In routine clinical practice, BTFC achieved consistent IOP lowering in both previously treated and untreated patients with primary open-angle glaucoma or ocular hypertension. BTFC was associated with significant IOP reductions, good tolerability, and good compliance.
    Read full Article
     
  • A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients.2
    Jothi R, Ismail AM, Senthamarai R, Pal S.
    Indian J Pharmacol. 2010 Dec;42(6):362-5. doi: 10.4103/0253-7613.71917.

    Objective: This study was designed to compare the bimatoprost/timolol combination and dorzolamide/timolol combination in glaucoma for efficacy, safety, and cost-effectiveness in a local population of Trichy in the state of Tamilnadu.
    Conclusion: The fixed combination of bimatoprost/timolol was slightly more effective than that of dorzolamide/timolol combination in reducing IOP, and both treatments were generally well tolerated. Bimatoprost/timolol combination was more cost-effective (cost-effective analysis) than dorzolamide/timolol combination.
    Read full Article

Guidelines

Overview of Disease

"Chronic open angle glaucoma (COAG) is a common and potentially blinding condition. It is usually asymptomatic until advanced and many people will be unaware there is a problem with their eyes until severe visual damage has occurred. Ocular hypertension (OHT) is a major risk factor for developing COAG, although COAG can occur with or without raised eye pressure."3

References

  1. Pfennigsdorf S, de Jong L, Makk S, Fournichot Y, Bron A, Morgan-Warren RJ, Maltman J. A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1219-25. doi: 10.2147/OPTH.S41885. Epub 2013 Jun 21.
  2. Jothi R, Ismail AM, Senthamarai R, Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. Indian J Pharmacol. 2010 Dec;42(6):362-5. doi: 10.4103/0253-7613.71917.
  3. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. 2009.

Ganfort Marketing Information

Ganfort Generic Name
Bimatoprost / Timolol
Marketing Company
Allergan Pharmaceuticals Ireland
Drug Type
POM
Date of Issue, Marketing Authority

19/05/2006

Related Drugs - Eye Health and Disorders

Back to top